Claims for Patent: 10,280,208

Summary for Patent: 10,280,208

Title:	TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
Abstract:	Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
Inventor(s):	Zang; Xingxing (New York, NY), Chinai; Jordan M. (Bronx, NY), Janakiram; Murali (Brooklyn, NY), Almo; Steven C. (Pelham, NY), Fiser; Andras (New York, NY)
Assignee:	Albert Einstein College of Medicine (Bronx, NY)
Application Number:	15/300,294
Patent Claims:	1. A method of treating an HHLA2-bearing tumor in a subject comprising administering to the subject an amount of a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor, wherein: the fusion protein comprises consecutive amino acid residues having the sequence set forth in SEQ ID NO:2 or in SEQ ID NO:3. 2. The method of claim 1 wherein the fusion protein comprising an IgV-like domain of a TMIGD2 comprises an Fc portion of an immunoglobulin G. 3. The method of claim 1 wherein the C-terminal residue of the IgV-like domain of a TMIGD2 of the fusion protein is fused via a peptide bond to an N-terminal residue of an Fc portion of an immunoglobulin G. 4. The method of claim 2, wherein the immunoglobulin G has the sequence of a human immunoglobulin G. 5. The method of claim 2, wherein the immunoglobulin G is an immunoglobulin G1. 6. The method of claim 1, wherein the IgV-like domain of the TMIGD2 is conjugated to a cytotoxic agent, and/or wherein the fusion protein is administered in combination with radiation therapy. 7. The method of claim 1, wherein the IgV-like domain of the TMIGD2 comprises consecutive amino acid residues having the sequence set forth in SEQ ID NO:5. 8. The method of claim 1, wherein administration of the fusion protein inhibits immunosuppression by the HHLA2-bearing tumor. 9. The method of claim 1, wherein the HHLA2 of the HHLA2-bearing tumor is a human HHLA2. 10. The method of claim 1, wherein the HHLA2-bearing tumor is a tumor of a breast, lung, thyroid, melanoma, pancreas, ovary, liver, bladder, colon, prostate, kidney, or esophagus, or is a hematological tumor. 11. The method of claim 10, wherein the HHLA2-bearing tumor is a hematological tumor and is a leukemia or a lymphoma. 12. The method of claim 10, wherein the HHLA2-bearing tumor is a tumor of the breast and is a triple negative breast cancer. 13. The method of claim 1, wherein the fusion protein comprises consecutive amino acid residues having the sequence set forth in SEQ ID NO:2. 14. The method of claim 1, wherein the fusion protein comprises consecutive amino acid residues having the sequence set forth in SEQ ID NO:3.

Details for Patent 10,280,208

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Ag	CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN	immune globulin intravenous (human)	For Injection	102367	07/27/2000		2034-04-30
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	07/26/2007		2034-04-30
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	10/02/2009		2034-04-30